Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy

Sonja Ständer, Dorothee Siepmann, Ilka Herrgott et al. · 2010

Read Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy by Sonja Ständer, Dorothee Siepmann, Ilka Herrgott et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010968.txt.

Description

Sonja Ständer, Dorothee Siepmann, Ilka Herrgott and co-authors published this itch treatment study in PLOS ONE in 2010. Chronic itching can wreck quality of life, arises from kidney, liver, and skin diseases that often cannot be cured, and frequently ignores antihistamines. Substance P, a nerve messenger, is a major driver of itch and acts through a receptor called NKR1, so the team tried blocking that receptor.

Twenty patients whose itch had resisted all standard treatment took the blocker aprepitant, an existing anti-nausea drug, for one week. Four out of five patients reported a considerable drop in itch intensity on a standard rating scale. Ständer and colleagues present the first clinical hint that this pathway can be drugged in people. A repurposed drug offering relief where nothing worked would be significant for a neglected symptom.

Catalog record

CREATORSonja Ständer, Dorothee Siepmann, Ilka Herrgott et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010968

Browse the full library · About the Tower of Babel